Basking Biosciences Reports Positive Phase 1 Data for BB-025
RESEARCH TRIANGLE, North Carolina — August 25, 2026 Basking Biosciences announced positive topline Phase 1 data for BB-025, an...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RESEARCH TRIANGLE, North Carolina — August 25, 2026 Basking Biosciences announced positive topline Phase 1 data for BB-025, an...
RESEARCH TRIANGLE, N.C., July 30, 2026 Basking Biosciences has announced the publication of groundbreaking preclinical research in Communications Biology,...
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, July 12, 2026 Hemab Therapeutics announced encouraging new clinical findings from its HMB-002 program...
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
